Cumulus Neuroscience, a global digital health company, announced the publication of final results from its CNS-101 study in Frontiers in Digital Health. The study demonstrates that the NeuLogiq Platform can be successfully used over a full year by patients living with mild Alzheimer’s disease dementia. Patients completed 99.7% of initiated sessions and maintained 77% adherence to a demanding 52-week protocol, compared to 88.8% adherence for healthy controls.
First Deployment in Alzheimer’s Dementia Patients
This is the first deployment of the platform in patients diagnosed with Alzheimer’s disease dementia. It addresses a recognized measurement gap in a field where standard clinical endpoints—the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating (CDR) scale—rely on infrequent, clinic-based ‘snapshot’ assessments prone to rater error and limited sensitivity to early change.
High Adherence and Usability Over 52 Weeks
High adherence and positive usability ratings sustained over 52 weeks support the use of objective, frequent, home-based digital biomarkers spanning cognition, EEG, and sleep. This approach enables more sensitive, lower-burden Alzheimer’s disease clinical trials. The study enrolled 119 participants—59 with mild Alzheimer’s disease dementia and 60 age-matched healthy controls—across seven UK clinical sites. Participants used the platform unsupervised at home over 52 weeks, with supervised in-clinic visits at baseline, week 26, and week 52.
Addressing Limitations of Traditional Endpoints
Alzheimer’s disease research has long relied on clinician-administered, pen-and-paper endpoints, most notably the ADAS-Cog and the CDR scale, to measure cognitive decline and treatment response. These tools provide infrequent ‘snapshot’ assessments, are prone to errors of administration and scoring, and have limited sensitivity to subtle, early-stage changes that disease-modifying trials increasingly need to detect. These limitations increase the scale, duration, and cost of clinical trials and can obscure treatment effects.
NeuLogiq Platform Design
The NeuLogiq Platform was designed in collaboration with ten top pharmaceutical companies to address these limitations by providing objective measures of brain function. The platform combines a self-setup wireless dry-sensor EEG headset—an FDA 510(k)-cleared and UKCA-marked Class 1 medical device—with tablet-based gamified neurocognitive assessments based on well-established paradigms. It integrates third-party assessments and features a cloud-based infrastructure.
Expert Commentary
“This study represents an important milestone for the NeuLogiq Platform and for the wider effort to bring more sensitive, real-world measurement to Alzheimer’s disease,” said Brian Murphy, PhD, Co-Founder and Chief Scientific Officer of Cumulus. “What stands out is that people living with mild dementia—not only healthy volunteers—were able and willing to use an EEG headset and complete cognitive tasks in their own homes—unsupervised, for a full year—finishing almost every session they began. That combination of high adherence and genuine patient acceptability in this population is an important foundation for designing trials that track disease progression more frequently and more precisely, while reducing the burden on patients and the cost and duration of studies.”
